During the past two decades many different treatment regimens of combination
chemotherapy have been applied in extensive stage small-cell lung cancer (SCLC). This …

For patients with small cell lung cancer (SCLC) in their early stages (TNM I, II), surgery for
cure was used to eliminate the primary tumour and its regional lymph-nodes followed by …

Systemic treatment in small cell lung carcinoma has been a challenge for oncologists for
decades. The high propensity for recurrence is usually due to distant metastasis, which …

Purpose Considering promising results in phase II studies, a randomized phase III trial was
designed to assess the efficacy of adding bevacizumab to first-line cisplatin plus etoposide …

7046 Background: Superiority of irinotecan/cisplatin combination over etoposide/cisplatin
has recently been suggested in a small phase III study in patients with small cell lung cancer …

Chemotherapy with a combination of cisplatin (60 mg/m2), Adriamycin (45 mg/m2), and
etoposide (120 mg/m2 x 3)(CAV) has been evaluated in 36 patients with small‐cell …

A total of 144 patients with small-cell lung cancer (SCLC) were randomized to receive
cisplatin/etoposide (PE) or ifosfamide/etoposide (IE) combination chemotherapy. PE …

Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six
cycles at 3-week intervals of etoposide 120 mg/m 2 iv on day 1 and orally on days 2–5 …

Thirty-three patients with limited small cell lung cancer (SCLC) received carboplatin,
epirubicin and VP-16 chemotherapy, concurrent 'split course'thoracic radiotherapy, followed …

Forty‐seven consecutive patients with small cell lung cancer (SCLC) were treated with a
combination chemotherapy program including 60 mg/m2 of cisplatin (P) on day 1 and 120 …